U.S. Markets closed

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
62.12+1.21 (+1.99%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close60.91
Open60.62
Bid56.50 x 1200
Ask66.00 x 1400
Day's Range58.85 - 62.16
52 Week Range25.49 - 62.16
Volume464,724
Avg. Volume782,529
Market Cap5B
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study
    Zacks

    Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study

    Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.

  • Apellis-Sobi Partnered Pegcetacoplan Shows Clinically Meaningful Improvements in Rare Blood Disorder Study
    Benzinga

    Apellis-Sobi Partnered Pegcetacoplan Shows Clinically Meaningful Improvements in Rare Blood Disorder Study

    Apellis Pharmaceuticals Inc (NASDAQ: APLS) and Swedish Orphan Biovitrum AB (SOBI) have reported positive top-line results from the Phase 3 PRINCE study evaluating Empaveli (pegcetacoplan) in treatment naïve paroxysmal nocturnal hemoglobinuria (PNH) patients. Empaveli demonstrated statistical superiority on the co-primary endpoints of hemoglobin stabilization and reduction in lactate dehydrogenase (LDH) compared to standard of care, which did not include complement inhibitors, at Week 26. 86% of Empaveli-treated patients achieved hemoglobin stabilization compared to 0% of patients on standard of care. Mean LDH in the Empaveli group decreased by 90% from a baseline, compared to 14%. Mean hemoglobin levels in the Empaveli group increased from 9.4 g/dL to 12.1 g/dL compared to an increase from 8.7 g/dL to 9.4 g/dL on the standard of care. 91% of patients on Empaveli were transfusion-free compared to 22% on the standard of care. On the safety front, 9% of patients in the Empaveli group experienced a serious adverse event compared to 17% on the standard of care. One death was reported in each group, and neither was related to treatment. Detailed results from the PRINCE study will be presented at medical congresses. Empaveli is approved in the U.S. for PNH, a rare blood disorder characterized by the destruction of oxygen-carrying red blood cells through extravascular and intravascular hemolysis. Price Action: APLS shares are trading higher by 9.75% at $51.80 in the premarket session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaApellis Stock Is Trading Higher On FDA Approval For Empaveli In Rare Blood Disorder© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug
    Zacks

    Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug

    Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.